X0306 4 2021-10-13 0001782223 Pyxis Oncology, Inc. PYXS 0001734389 Chin Mark C/O PYXIS ONCOLOGY, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 true Common Stock 2021-10-13 4 C 0 1433261 A 1433261 I See footnote Common Stock 2021-10-13 4 P 0 312500 16 A 1745761 I See footnote Series B Convertible Preferred Stock 2021-10-13 4 C 0 9114109 0 D Common Stock 1433261 0 I See footnote These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein. /s/ Pamela Connealy, Attorney-in-Fact for Mark Chin 2021-10-15